803,888 Shares in Amarin Co. plc (AMRN) Acquired by University of Notre Dame DU Lac

University of Notre Dame DU Lac purchased a new position in shares of Amarin Co. plc (NASDAQ:AMRN) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 803,888 shares of the biopharmaceutical company’s stock, valued at approximately $2,814,000. University of Notre Dame DU Lac owned about 0.30% of Amarin as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in AMRN. Intrinsic Edge Capital Management LLC acquired a new position in Amarin in the 2nd quarter valued at $725,000. OxFORD Asset Management LLP grew its stake in Amarin by 114.2% in the 2nd quarter. OxFORD Asset Management LLP now owns 135,773 shares of the biopharmaceutical company’s stock valued at $547,000 after buying an additional 72,390 shares during the last quarter. JPMorgan Chase & Co. grew its stake in Amarin by 681.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 278,134 shares of the biopharmaceutical company’s stock valued at $1,121,000 after buying an additional 242,544 shares during the last quarter. Dynamic Technology Lab Private Ltd grew its stake in Amarin by 94.2% in the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 87,104 shares of the biopharmaceutical company’s stock valued at $351,000 after buying an additional 42,246 shares during the last quarter. Finally, GSA Capital Partners LLP grew its stake in Amarin by 135.4% in the 2nd quarter. GSA Capital Partners LLP now owns 342,800 shares of the biopharmaceutical company’s stock valued at $1,381,000 after buying an additional 197,200 shares during the last quarter. Institutional investors own 40.17% of the company’s stock.

In other Amarin news, insider John F. Thero acquired 10,000 shares of Amarin stock in a transaction dated Thursday, November 30th. The stock was bought at an average cost of $3.24 per share, with a total value of $32,400.00. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Steven B. Ketchum sold 63,479 shares of the firm’s stock in a transaction dated Thursday, October 5th. The stock was sold at an average price of $3.48, for a total transaction of $220,906.92. The disclosure for this sale can be found here. 3.72% of the stock is currently owned by company insiders.

A number of research analysts recently issued reports on the stock. BidaskClub lowered shares of Amarin from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Amarin in a research note on Wednesday, August 9th. Cantor Fitzgerald reiterated a “buy” rating and issued a $10.00 target price on shares of Amarin in a research note on Tuesday, September 26th. ValuEngine lowered shares of Amarin from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Finally, Zacks Investment Research upgraded shares of Amarin from a “hold” rating to a “buy” rating and set a $4.00 price target on the stock in a research report on Tuesday, October 3rd. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $7.75.

Shares of Amarin Co. plc (NASDAQ:AMRN) opened at $3.06 on Wednesday. The company has a quick ratio of 1.32, a current ratio of 1.63 and a debt-to-equity ratio of -1.48. Amarin Co. plc has a 12-month low of $2.81 and a 12-month high of $4.47.

Amarin (NASDAQ:AMRN) last posted its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.01. The company had revenue of $47.10 million during the quarter, compared to analyst estimates of $45.85 million. The business’s revenue for the quarter was up 45.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.08) earnings per share. equities analysts expect that Amarin Co. plc will post -0.22 EPS for the current year.

TRADEMARK VIOLATION WARNING: This report was first posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.com-unik.info/2017/12/06/803888-shares-in-amarin-co-plc-amrn-acquired-by-university-of-notre-dame-du-lac.html.

Amarin Company Profile

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Institutional Ownership by Quarter for Amarin (NASDAQ:AMRN)

What are top analysts saying about Amarin Co. plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amarin Co. plc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit